Monoclonal Antibodies and Therapeutic Perspectives
Monoclonal Antibodies: Therapeutic Precision in the Age of Immunotherapy
Monoclonal antibodies (mAbs) have revolutionized diagnostic and therapeutic medicine through their molecular specificity. This article explores their origin in humoral immunity, the differences between polyclonal and monoclonal responses, and their applications in research, diagnostics, and treatment of cancer and infectious diseases. It highlights the impact of immune checkpoint mAbs—recognized with the Nobel Prize—and concludes with a reflection on their future and an invitation to explore advanced therapies.
From Natural Immunity to Therapeutic Design
The recognition of the protective effect of serum from convalescent patients with infectious diseases marked a turning point in the development of preventive medicine.
Antibodies, also called immunoglobulins (Ig), are specialized glycoproteins that are part of humoral immunity. They are produced by B cells of the immune system, which recognize specific molecules called antigens.
When an organism is exposed to one or more antigens, a polyclonal response is generated. This means that multiple B lymphocytes, each with a different receptor, are activated and produce antibodies against different epitopes of the same antigen. This diversity allows for a more robust and adaptable immune response, covering different aspects of the pathogen or foreign structure. For example, in a respiratory virus infection, antibodies are generated against different viral proteins…
On the other hand, the monoclonal response is based on the activation of a single clone of B cells that recognizes a unique antigenic determinant. From this cell, an immortalized cell line can be generated—as in hybridoma technology—which produces large quantities of a single type of antibody with unique specificity. This homogeneity is what gives monoclonal antibodies their value in diagnostics and specific therapies, although it also means their effect is limited to the specific antigenic target they…
General Applications of Monoclonal Antibodies
Due to their high specificity and affinity for a target molecule, monoclonal antibodies (mAbs) have become fundamental tools in biomedical and clinical research. Some of their applications include:
- Detection and quantification of gene expression levels: using techniques such as ELISA or Western blot to measure disease-associated proteins, e.g., HER2 in breast cancer.
- Cellular and tissue localization of gene products: using immunohistochemistry to detect proteins like p53 in tumor biopsies.
- Identification of molecular interactions (e.g., immunoprecipitation): studying protein-protein complexes like cell surface receptor assemblies.
- Phenotypic characterization of lymphocytes and phagocytes: using flow cytometry to identify relevant subtypes in diseases like leukemia.
- Immunodiagnosis of infectious and systemic diseases: detecting dengue virus antigens or antinuclear antibodies in autoimmune conditions.
- Diagnosis and treatment of specific cancers: using labeled mAbs for PET imaging or administering trastuzumab in HER2-positive breast cancer.
- Functional analysis of proteins and cell surface receptors: blocking proteins such as PD-1 or CTLA-4 to study their role in immune evasion in cancer.
- Study of host-pathogen interactions: mAbs help identify how pathogens like Mycobacterium tuberculosis interact with macrophages.
- Vaccine development and immunotherapeutic strategies: anti-idiotype mAbs can mimic antigens to train the immune system against specific diseases.
Clinical Applications of Monoclonal Antibodies
Therapeutically, over 29 mAbs have been approved by the FDA, and around 150 are in clinical trials. Notable examples include:
- Muromonab-CD3 (Orthoclone OKT3®): the first approved mAb, used to prevent kidney transplant rejection. It selectively suppresses activated T lymphocytes.
- Nebacumab (Centoxin®): targeted endotoxins from Gram-negative bacteria in sepsis. Withdrawn after increased mortality was observed.
- Tecnemab K1®: anti-melanoma antibody labeled with technetium-99 for imaging via immunoscintigraphy. Used to locate ocular melanoma metastases. Withdrawn due to low effectiveness.
- Igovomab (Indimacis 125®): antibody fragment specific for CA-125, a marker in ovarian cancer. Enabled detection of recurrences via nuclear imaging. Withdrawn in 1999.
- Votumonab (Humaspect®): designed to recognize cytokeratins in colon adenocarcinoma. Though promising for diagnostic imaging, it was never approved.
- Immune checkpoint monoclonal antibodies (e.g., anti-PD-1 and anti-CTLA-4): represent one of the most important advances in cancer immunotherapy. These antibodies unlock the immune system’s response against tumor cells. Their impact was so significant that their discoverers, James P. Allison and Tasuku Honjo, were awarded the Nobel Prize in Physiology or Medicine in 2018. Drugs such as nivolumab or ipilimumab have revolutionized the prognosis of various cancers, including melanoma and lung cancer.
Final Reflections
The development of monoclonal antibodies marks a turning point in modern medicine. Their ability to combine molecular specificity with precise therapeutic and diagnostic applications has reshaped how we understand and treat many diseases. From lab bench to clinical use, mAbs remain a cutting-edge tool evolving rapidly with scientific rigor. The current challenge lies in making them more accessible, reducing costs, and continually enhancing their safety and efficacy so that more patients can benefit.
At Baja Regenerative, we closely follow the advancement of therapies based on monoclonal antibodies. If you are a healthcare professional interested in their clinical application or a patient seeking advanced therapeutic options, contact us to receive specialized guidance and learn more about our immunotherapy and personalized medicine programs.
References:
Sindelar RD. Pharmaceutical biotechnology. An introduction for pharmacists and pharmaceutical Scientists. 1st ed. Amsterdam: Harwood Academic Publisher; 1997. p.288-9.
Rojas W, Cano LE. Inmunología. 12a edición. Medellín: Corporación para Investigaciones Biológicas; 2001. p.155-6.
Gavilondo JV. Anticuerpos monoclonales. Teoría y práctica. La Habana: Elfos Scienticiae; 1995. p.47-51.
Bona CA, Bonilla FA. Textbook of immunology. Second edition. Amsterdam: Harwood Academic Publisher; 1990.
Bruggemann M, Caskey HM, Teale C, Waldmann H, Williams GT, Surani MA, Neuberger MS. A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc Natl Acad Sci USA. 1989;86:6709-13.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Listing of approved oncology drugs with approved indications. Disponible en: http://www.fda.gov/cder/cancer/druglistframe.htm (30 de enero de 2006).
Bakr MA. Induction therapy. Exp Clin Transplant. 2005;3:320-8.
Machado, N. P., Téllez, G. A., & Castaño, J. C. (2006). Anticuerpos monoclonales: desarrollo físico y perspectivas terapéuticas. Infectio, 10(3), 186–197.
